Lupin to acquire Dutch ophthalmology firm VISUfarma

Drugmaker Lupin will acquire Dutch firm VISUfarma in a transaction that pegs the enterprise worth of the Amsterdam-based specialty pharmaceutical firm targeted on ophthalmology at euro 190 million.

A portfolio firm of worldwide healthcare specialist investor GHO Capital Partners LLP, VISUfarma gives merchandise within the areas of dry eye, glaucoma, eyelid hygiene, blepharitis, retinal well being and nutraceuticals. It has a industrial presence throughout main European nations, together with Italy, the UK, Spain, Germany and France, Lupin stated on Monday (September 29), saying signing of a definitive settlement by subsidiary Nanomi B.V., for the acquisition.

VISUfarma’s operations will present market enlargement alternatives, direct presence and additional enterprise diversification throughout main European nations. The portfolio of greater than 60 branded ophthalmology merchandise will current development alternatives to speed up enlargement into the specialty section throughout areas and projected to drive development in Europe in addition to in different markets, Lupin stated.

The transaction, primarily based on euro 190 million VISUfarma’s enterprise worth, will likely be topic to customary closing circumstances and anticipated to be accomplished by December. Lupin will finance the acquisition via inside accruals. “Beyond being instantly accretive, it additionally broadens our presence in Europe and additional builds our specialty franchise in Ophthalmology, Lupin CEO Vinita Gupta stated.

The acquisition aligns with Lupin’s technique to increase European enterprise and footprint and advance the corporate’s international specialty franchise. By integrating VISUfarma’s established industrial operations, Lupin stated it’s going to faucet into the engaging ophthalmology market, which is experiencing vital international development pushed by an ageing international inhabitants, the rising incidence of diabetes-related eye issues, and rising consciousness of preventive care.

GHO Capital has reworked VISUfarma from a home Italian ophthalmic participant into a novel pan-European enterprise with established operations throughout key markets, a strong product portfolio masking the primary illness areas impacting each the entrance and back-of-the-eye, and the infrastructure to proceed its development trajectory, stated Andrea Ponti, Managing Partner and Mike Turner, Partner at GHO Capital. VISUfarma had clocked consolidated income of euro 48.1 million and web value of euro 134.6 million in 2024.